NCT00849654已完成1 期
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 66
- 试验地点
- 9
- 主要终点
- Dose limiting toxicity assessment for each patient.
研究概览
简要总结
The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women and men ≥ 18 years of age. There is no experience with this drug in a pediatric population.
- •Body weight ≥ 40 kg.
- •Recurrent surface immunoglobulin positive B cell non-Hodgkin's lymphoma (NHL) according to WHO classification, including small lymphocytic lymphoma/ chronic lymphocytic leukemia (SLL/CLL) lymphoplasmacytic lymphoma, including Waldenström's Macroglobulinemia (WM), and pre-identified DLBCL ABC subtype oFor the DLBCL-ABC cohort, documented, activated B-cell subtype by either immunohistochemistry or tissue microarray analysis.
- •Measurable disease (for NHL, bidimensional disease ≥ 2 cm diameter in at least one dimension, for CLL ≥ 5000 leukemia cells/mm3, for WM presence of immunoglobulin M paraprotein with a minimum IgM level ≥ 1000 mg/dL and infiltration of bone marrow by lymphoplasmacytic cells), and pre-identified DLBCL ABC subtype by immunohistochemistry (IHC).
- •Have failed ≥ 1 previous treatment for lymphoma and no standard therapy is available. Patients with diffuse large B cell lymphoma must have failed, refused or be ineligible for autologous stem cell transplant.
- •ECOG performance status of ≤
- •Ability to swallow oral capsules without difficulty.
- •Willing and able to sign a written informed consent.
排除标准
- •More than four prior systemic therapies (not counting maintenance rituximab), except for CLL patients. Salvage therapy/conditioning regimen leading up to autologous bone marrow transplantation is considered to be one regimen (This inclusion criterion does not apply to the DLBCL-ABC cohort).
- •Prior allogeneic bone marrow transplant.
- •Immunotherapy, chemotherapy, radiotherapy or experimental therapy within 4 weeks before first day of study drug dosing.
- •Major surgery within 4 weeks before first day of study drug dosing.
- •CNS involvement by lymphoma.
- •Active opportunistic infection or treatment for opportunistic infection within 4 weeks before first day of study drug dosing.
- •History of malabsorption.
- •Laboratory abnormalities:
- •Creatinine > 1.5 × institutional upper limit of normal (ULN)
- •Total bilirubin > 1.5 x institutional ULN (unless elevated from documented Gilbert's syndrome)
- •AST or ALT > 2.5 × institutional ULN
- •Platelet count < 75,000/µL (unless patients have CLL and bone-marrow involvement, provided they are not transfusion-dependent)
- •Absolute neutrophil count (ANC) < 1500/µL (unless patients have CLL and bone-marrow involvement)
- •Hgb < 8.0 g/dL
- •Uncontrolled illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV heart failure), unstable angina pectoris, cardiac arrhythmia, and psychiatric illness that would limit compliance with study requirements.
- •Risk factors for, or use of medications known to prolong QTc interval or that may be associated with Torsades de Pointes within 7 days of treatment start.
- •QTc prolongation (defined as a QTc > 450 msecs) or other significant ECG abnormalities including 2nd degree AV block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min). If the screening ECG has a QTc > 450 msecs, the ECG can be submitted for a centralized, cardiologic evaluation.
- •History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty and/or stenting within the past 6 months.
- •Known HIV infection.
- •Hepatitis B sAg or Hepatitis C positive.
- •Other medical or psychiatric illness or organ dysfunction which, in the opinion of the investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of the study agent.
- •Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound).
- •Women of child-bearing potential or sexually active men, unwilling to use adequate contraceptive protection during the course of the study.
- •History of prior cancer < 2 years ago, except for basal cell or squamous cell carcinoma of the skin, cervical cancer in situ or other in situ carcinomas.
研究组 & 干预措施
PCI-32765
Experimental
干预措施: PCI-32765 (Drug)
结局指标
主要结局
Dose limiting toxicity assessment for each patient.
时间窗: At the end of the first 35 day cycle
Pharmacokinetic/ Pharmacodynamic assessments
时间窗: during Cycle 1
Adverse events
时间窗: 30 days after last dose of study drug
次要结局
- Tumor response(at the end of Cycles 2, 4, and 6 unitl progression)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
1 期
Safety of PCI-32765 in Chronic Lymphocytic LeukemiaB-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNCT01105247Pharmacyclics LLC.133
已完成
2 期
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT01478581Pharmacyclics LLC.92
终止
2 期
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin TherapyGlioblastoma MultiformeNCT02047214Cortice Biosciences, Inc.17
已完成
1 期
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's DiseaseAlzheimer's DiseaseNCT01966666University of California, San Francisco29
终止
1 期
Study Evaluating TTI-237 in Advanced Malignant Solid TumorsNeoplasmsNCT00195247Wyeth is now a wholly owned subsidiary of Pfizer45